Jonathan H. Goldman

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 329 citations

Cardiomyopathy, Heart Failure, Omecamtiv Mecarbil +10

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali et al. · The Lancet · 2011 · 260 citations

Cardiac Muscle, Cardiomyopathy, Omecamtiv Mecarbil +12

Thinking Outside the “Box”—The Ultrasound Contrast Controversy

Michael L. Main, Jonathan H. Goldman, Paul Grayburn · Journal of the American College of Cardiology · 2007 · 120 citations

Medical Ultrasound, Cognitive Science, Focused Ultrasound +8

Comparison of usefulness of dipyridamole stress myocardial contrast echocardiography to technetium-99m sestamibi single-photon emission computed tomography for detection of coronary artery disease (PB127 Multicenter Phase 2 Trial results)

Kevin Wei, Linda J. Crouse, James L. Weiss et al. · The American Journal of Cardiology · 2003 · 101 citations

Vascular Image, Health Sciences, Cardiovascular Disease +11

QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy

L. Fei, Jonathan H. Goldman, Krishna Prasad et al. · European Heart Journal · 1996 · 92 citations · Full text

Qt Dispersion Assessment, Heart Failure, Rr Variations +15